Saddle Pulmonary Embolism in a Cancer Patient with Thrombocytopenia: A Treatment Dilemma

Table 3

Multivariate analysis of the risk of developing fatal and major bleeding in cancer patients with venous thromboembolism (VTE) [31, 32].

	Fatal bleeding		Major bleeding
Variables	Odds ratio (95% CI)	𝑃-value	Variables	Odds ratio (95% CI)	𝑃-value
Body weight <60 kg	2.5 (1.1–5.3)	.021	Recent major bleeding	2.4 (1.1–5.1)	.003
Recent major bleeding	3.0 (0.96–9.1)	.058	CrCl < 30 ml/min	2.2 (1.5–3.4)	<.001
Serum creatinine >1.2 mg/dL	2.8 (1.3–5.8)	.008	Immobility for ≥4 days	1.8 (1.2–2.7)	.005
Immobility for ≥4 days	4.1 (1.9–8.7)	.001	Metastatic cancer	1.6 (1.1–2.3)	.03
Metastatic cancer	3.1 (1.4–7.1)	.006

Confidence interval: CI; creatinine clearance: CrCl.